Alvaro Teijeira

List of Publications by Year
in descending order

66	4,066	147801	161849
papers	citations	31 h-index	54 g-index

66	66	66	6968
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis. Cancer Letters, 2022, 529, 70-84.	7.2	51
2	Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer. Cancer Discovery, 2022, 12, 1356-1377.	9.4	22
3	Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies. , 2022, 10, e003532.		8
4	Novel strategies exploiting interleukin-12 in cancer immunotherapy. , 2022, 239, 108189.		35
5	A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFÎ±, and IL-1Î². Cancer Discovery, 2022, 12, 2140-2157.	9.4	16
6	Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis. OncoImmunology, 2022, 11, .	4.6	3
7	Mouse Models of Peritoneal Carcinomatosis to Develop Clinical Applications. Cancers, 2021, 13, 963.	3.7	12
8	Differential Interleukinâ€8 thresholds for chemotaxis and netosis in human neutrophils. European Journal of Immunology, 2021, 51, 2274-2280.	2.9	32
9	Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	24
10	Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on <scp>IL</scp>â€8. Journal of Pathology, 2021, 255, 190-201.	4.5	49
11	Firefighters for the Wrong Type of Inflammation in Tumors. Cancer Discovery, 2021, 11, 2372-2374.	9.4	3
12	IL8, Neutrophils, and NETs in a Collusion against Cancer Immunity and Immunotherapy. Clinical Cancer Research, 2021, 27, 2383-2393.	7.0	108
13	Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy. , 2021, 9, e002953.		23
14	CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation. Nature Communications, 2021, 12, 7296.	12.8	22
15	Repurposing the yellow fever vaccine for intratumoral immunotherapy. EMBO Molecular Medicine, 2020, 12, e10375.	6.9	28
16	CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity. Immunity, 2020, 52, 856-871.e8.	14.3	387
17	Cellular cytotoxicity is a form of immunogenic cell death. , 2020, 8, e000325.		61
18	Human CD8 T cells are susceptible to TNF-mediated activation-induced cell death. Theranostics, 2020, 10, 4481-4489.	10.0	24

#	Article	IF	Citations
19	Engineering bionic T cells: signal 1, signal 2, signal 3, reprogramming and the removal of inhibitory mechanisms. Cellular and Molecular Immunology, 2020, 17, 576-586.	10.5	12
20	The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. , 2019, 7, 109.		129
21	Immunotherapeutic effects of intratumoral nanoplexed poly I:C. , 2019, 7, 116.		91
22	Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature, 2019, 569, 428-432.	27.8	313
23	Dendritic Cells and T Cells Interact Within Murine Afferent Lymphatic Capillaries. Frontiers in Immunology, 2019, 10, 520.	4.8	23
24	New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis. ESMO Open, 2019, 4, e000733.	4.5	80
25	Metabolic Consequences of T-cell Costimulation in Anticancer Immunity. Cancer Immunology Research, 2019, 7, 1564-1569.	3.4	48
26	Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells. Cancer Cell, 2019, 36, 613-629.e7.	16.8	99
27	Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation. Cancer Immunology Research, 2018, 6, 798-811.	3.4	62
28	Co-stimulation Agonists via CD137, OX40, GITR, and CD27 for Immunotherapy of Cancer. , 2018, , 429-446.		0
29	Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4â€“1BB). OncoImmunology, 2018, 7, e1368605.	4.6	7
30	ICAM-1-LFA-1 Dependent CD8+ T-Lymphocyte Aggregation in Tumor Tissue Prevents Recirculation to Draining Lymph Nodes. Frontiers in Immunology, 2018, 9, 2084.	4.8	31
31	Intratumoral Immunotherapy with XCL1 and sFlt3L Encoded in Recombinant Semliki Forest Virusâ€“Derived Vectors Fosters Dendritic Cellâ€“Mediated T-cell Cross-Priming. Cancer Research, 2018, 78, 6643-6654.	0.9	60
32	Epistatic Oncogenic Interactions Determine Cancer Susceptibility to Immunotherapy. Cancer Discovery, 2018, 8, 794-796.	9.4	6
33	T Cell Migration from Inflamed Skin to Draining Lymph Nodes Requires Intralymphatic Crawling Supported by ICAM-1/LFA-1 Interactions. Cell Reports, 2017, 18, 857-865.	6.4	96
34	CD69 is a direct HIF-1Î± target gene in hypoxia as a mechanism enhancing expression on tumor-infiltrating T lymphocytes. OncoImmunology, 2017, 6, e1283468.	4.6	27
35	Cellular immunotherapies for cancer. OncoImmunology, 2017, 6, e1306619.	4.6	17
36	Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. Annals of Oncology, 2017, 28, xii44-xii55.	1.2	170

#	Article	IF	Citations
37	Interleukin-8 in cancer pathogenesis, treatment and follow-up. Cancer Treatment Reviews, 2017, 60, 24-31.	7.7	262
38	Microinjection for the ex Vivo Modification of Cells with Artificial Organelles. ACS Nano, 2017, 11, 7758-7769.	14.6	15
39	Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule Are Induced by Ionizing Radiation on Lymphatic Endothelium. International Journal of Radiation Oncology Biology Physics, 2017, 97, 389-400.	0.8	55
40	Cancer immunotherapy full speed ahead. Annals of Oncology, 2017, 28, xii1-xii2.	1.2	6
41	Abstract 639: Morphological changes in mitochondria induced by CD137 (4-1BB) co-stimulation on CD8 T cells. , 2017, , .		1
42	T Cell Trafficking through Lymphatic Vessels. Frontiers in Immunology, 2016, 7, 613.	4.8	121
43	Immunotherapy of Cancer Visualized by Live Microscopy: Seeing Is Believing. Clinical Cancer Research, 2016, 22, 4277-4279.	7.0	2
44	Intralymphatic CCL21 Promotes Tissue Egress of Dendritic Cells through Afferent Lymphatic Vessels. Cell Reports, 2016, 14, 1723-1734.	6.4	143
45	Cancer Immunosurveillance Caught in the Act. Immunity, 2016, 44, 525-526.	14.3	6
46	Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Antiâ€“PD-1 and Anti-CD137 Monoclonal Antibodies. Journal of Thoracic Oncology, 2016, 11, 524-536.	1.1	48
47	Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs). Clinical Cancer Research, 2016, 22, 3924-3936.	7.0	306
48	IL-1 Coordinates the Neutrophil Response to C. albicans in the Oral Mucosa. PLoS Pathogens, 2016, 12, e1005882.	4.7	98
49	Abstract 4015: Exposure of lymphatic endothelial cells to ionizing radiation increases the surface expression levels of integrin ligands. , 2016, , .		0
50	A Transgenic Prox1-Cre-tdTomato Reporter Mouse for Lymphatic Vessel Research. PLoS ONE, 2015, 10, e0122976.	2.5	41
51	Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7551-7556.	7.1	92
52	Editorial: Breaching their way through: Neutrophils destroy intercellular junctions to transmigrate rapidly across lymphatic endothelium. Journal of Leukocyte Biology, 2015, 98, 880-882.	3.3	5
53	Taking the lymphatic route: dendritic cell migration to draining lymph nodes. Seminars in Immunopathology, 2014, 36, 261-274.	6.1	54
54	Phosphorylated tubulin adaptor protein CRMPâ€2 as prognostic marker and candidate therapeutic target for NSCLC. International Journal of Cancer, 2013, 132, 1986-1995.	5.1	32

#	Article	IF	Citations
55	Lymphatic Endothelium Forms Integrin-Engaging 3D Structures during DC Transit across Inflamed Lymphatic Vessels. Journal of Investigative Dermatology, 2013, 133, 2276-2285.	0.7	48
56	Initial Afferent Lymphatic Vessels Controlling Outbound Leukocyte Traffic from Skin to Lymph Nodes. Frontiers in Immunology, 2013, 4, 433.	4.8	33
57	T Cell Costimulation with Anti-CD137 Monoclonal Antibodies Is Mediated by K63â€“Polyubiquitin-Dependent Signals from Endosomes. Journal of Immunology, 2013, 190, 6694-6706.	0.8	56
58	Abstract B2: T cell costimulation in cancer immunotherapy with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes.. , 2013, , .		0
59	The HIF-1Î± Hypoxia Response in Tumor-Infiltrating T Lymphocytes Induces Functional CD137 (4-1BB) for Immunotherapy. Cancer Discovery, 2012, 2, 608-623.	9.4	156
60	CD137 on inflamed lymphatic endothelial cells enhances CCL21â€guided migration of dendritic cells. FASEB Journal, 2012, 26, 3380-3392.	0.5	45
61	Abstract 3538: The HIF-1Î± hypoxia response in mouse tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. , 2012, , .		1
62	Agonist Anti-CD137 mAb Act on Tumor Endothelial Cells to Enhance Recruitment of Activated T Lymphocytes. Cancer Research, 2011, 71, 801-811.	0.9	137
63	Intratumoral injection of interferonâ€Î± and systemic delivery of agonist antiâ€CD137 monoclonal antibodies synergize for immunotherapy. International Journal of Cancer, 2011, 128, 105-118.	5.1	39
64	Abstract 4740: Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment ofactivated T lymphocytes. , 2011, , .		0
65	Dendritic cells adhere to and transmigrate across lymphatic endothelium in response to IFNâ€Î±. European Journal of Immunology, 2010, 40, 3054-3063.	2.9	49
66	Repetitive Nicotine Exposure Leads to a More Malignant and Metastasis-Prone Phenotype of SCLC: A Molecular Insight into the Importance of Quitting Smoking during Treatment. Toxicological Sciences, 2010, 116, 467-476.	3.1	36